As per management commentary in AR 2014-15, the Phase-Ib trials for SUVN 502 is completed and commenced preparations for the Phase-IIa (POC) trial. The management hope to initiate patient trials during the second half of the current year and are hopeful of monetising this molecule post successful completion of the study in fiscal 2017.
| Subscribe To Our Free Newsletter |
